Health‐Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer

BACKGROUND: MONARCH 3, a phase III trial (NCT02246621) of postmenopausal women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC), previously demonstrated significantly improved progression‐free survival in patients receiving...

Descripción completa

Detalles Bibliográficos
Autores principales: Goetz, Matthew P., Martin, Miguel, Tokunaga, Eriko, Park, In Hae, Huober, Jens, Toi, Masakazu, Stoffregen, Clemens, Shekarriz, Sarah, Andre, Valerie, Gainford, M. Corona, Price, Gregory L., Johnston, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485333/
https://www.ncbi.nlm.nih.gov/pubmed/32536013
http://dx.doi.org/10.1634/theoncologist.2020-0084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485333/
https://www.ncbi.nlm.nih.gov/pubmed/32536013
http://dx.doi.org/10.1634/theoncologist.2020-0084

Ejemplares similares